Previous Article | Next Article 
Journal of Virology, October 1998, p. 8174-8180, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Human Immunodeficiency Virus Type 1 Induction
Mediated by Genistein Is Linked to Cell Cycle Arrest in
G2
Joel
Gozlan,1,
Janet L.
Lathey,1 and
Stephen A.
Spector1,2,3,*
Department of
Pediatrics,1
Center for Molecular
Genetics,2 and
Center for AIDS
Research,3 University of California, San
Diego, La Jolla, California
Received 21 April 1998/Accepted 13 July 1998
 |
ABSTRACT |
Protein tyrosine kinase (PTK) phosphorylation is involved in
cellular proliferation and differentiation processes that are key
factors for human immunodeficiency virus type 1 (HIV-1) regulation in
infected monocytic cells. Short-term exposure of the chronically infected promyelocytic OM10 cell line with the PTK inhibitor genistein induced a dose-dependent increase in p24 antigen production in culture
supernatants. This induction persisted in the presence of the reverse
transcriptase inhibitor, zidovudine, and was associated with an
increased transcription of HIV-1 multiply spliced and unspliced RNAs,
suggesting a transcriptional mechanism targeting the integrated
provirus. Genistein induced cell differentiation, apoptosis, and a
G2 arrest in the OM10 cells. Cell
differentiation and apoptosis were not directly involved in the
observed increase in HIV-1 replication that was closely
linked to genistein-induced G2 arrest. Alleviation
of the G2 arrest by pentoxyfylline resulted in a
concomitant reduction of HIV-1 to baseline replication. Additionally, by flow cytometry, a significant increase in the number of p24 antigen-expressing cells was observed in cells arrested in
G2 compared to those located in G1 or S. Tyrosine kinase inhibition was found not to be essential for enhanced
viral replication, which seemed to be related to two other properties
of genistein, inhibition of topoisomerase II
activity and inhibition of phosphotidylinositol turnover. These
findings are consistent with the recent observation that HIV-1 Vpr
induces viral replication through preventing proliferation of cells by
arresting them in G2 of the cell cycle and strongly suggest
that manipulation of the cell cycle plays an important role in HIV-1
pathogenesis.
 |
INTRODUCTION |
Cells of monocyte/macrophage lineage
represent a major reservoir of human immunodeficiency virus type 1 (HIV-1) in vivo. Despite the usual absence of virus-induced
cytopathic effect, these cells produce high levels of virus, even at
the later stages of HIV-1 infection when CD+ T cells
are declining (30). Thus, the regulation of HIV-1
replication in monocytes/macrophages plays an important role in the
pathogenesis of AIDS and is particularly critical for HIV-1
persistence and dissemination in infected individuals.
Among the many factors able to influence the levels of HIV-1
replication in macrophages, proinflammatory cytokine production (for a
review, see reference 33), as well as the state of
cell activation and differentiation, seems to play an important
role. For this latter aspect, most studies have found that
cell maturation enhances HIV-1 replication, via
either an increased susceptibility of the cell to HIV-1 infection
(22, 36, 40) or an increase in viral transcription of a
quiescent provirus (7, 26). However, some reports have
recently demonstrated a dissociation between cell differentiation and
HIV-1 expression (15). The modulation of HIV-1
transcription after integration into host cell DNA is determined to a
great extent by the activity of the viral protein Tat on its
RNA-responsive element located in the long terminal repeat (LTR) and by
transcription factors acting on binding sites also located in the LTR
(for a review, see reference 14). The second
messenger systems, acting upstream of the transcriptional control of
the integrated provirus, are not fully characterized and probably
involve a complex network of protein phosphorylation and
dephosphorylation. Protein tyrosine kinase (PTK) phosphorylation plays
a crucial role in cell proliferation and differentiation and therefore
may also regulate some aspect of HIV-1 latency-reactivation in
infected cells. HIV-1 is known to increase the level of tyrosine phosphorylation of several proteins within the infected cells (4, 9, 31), involving the enhancement of the Src family PTK
activity. On the other hand, PTK is required for the
transduction of signals initiated by the action of lipopolysaccharide
on monocytes/macrophages (3, 42, 46, 47), leading to the
increase of several cytokines known to induce HIV-1 (3, 42,
46). However, the consequences of tyrosine kinase activation or
inhibition on HIV-1 expression itself have not been investigated.
While studying the effects of the tyrosine kinase inhibitor
genistein on HIV-1 expression in chronically infected
promyelocytic cells, we demonstrated a strong and dose-dependent
increase of HIV-1 expression. In the research described herein, we
have characterized this upregulation of HIV-1 replication in the
promyelocytic cell line OM10. The enhancement of HIV-1 appears to
be transcriptional, since both p24 antigen production and transcription
of viral RNAs are induced and persist in the presence of zidovudine. We
also present evidence that arrest of cells in G2 is
critical for the increase in HIV-1 expression. Finally, the ability
of genistein to inhibit topoisomerase II activity
and phosphotidylinositol turnover seems to be important in the
upregulation of HIV-1 rather than its inhibition of PTK.
 |
MATERIALS AND METHODS |
Cells and chemicals. (i) Cell lines.
Two cell lines were
used for these experiments: the OM10 cell line, which is a chronically
infected promyelocytic clone (LAI strain) harboring a single proviral
DNA integrated in the chromosome, a low basal HIV-1 expression, and
a persistent surface expression of CD4 until HIV-1 activation; and
the U1 cell line, which is a more differentiated promonocytic clone,
containing two integrated copies of provirus and also expressing low
levels of virus until HIV-1 activation. Both cell lines were
obtained from the National Institutes of Health AIDS Research and
Reference Reagent Program and maintained in RPMI 1640 complemented with
10% fetal calf serum and antibiotics. Cells were resuspended at 5 × 105 cells/ml prior to stimulation.
(ii) Reagents.
Genistein, herbimycin A,
psi-tectorigenin, and etoposide were purchased from Calbiochem (La
Jolla, Calif.) and diluted in dimethyl sulfoxide (DMSO) prior to use.
The final concentration of DMSO in the cultures never exceeded 0.2%
(vol/vol). Pentoxyfylline (Sigma, Carpinteria, Calif.) was diluted in
water as a 500× stock solution (500 mM). A stock solution of
dihydroxyvitamin D3 (Sigma) was dissolved in ethanol and
preserved at
80°C until final dilution (10
7 M) in
RPMI. Nonspecific esterase (NSE) activity was determined on a cytospin
preparation of the cells, by a staining procedure, according to the
manufacturer's protocol (
-naphthyl acetate esterase staining kit;
Sigma).
(iii) Cytokine quantification.
Tumor necrosis factor alpha
(TNF-
) present in the supernatants of the cells was quantified by
enzyme-linked immunosorbent assay (ELISA) (Biosource, Camarillo,
Calif.) according to the manufacturer's protocol.
HIV-1 expression. (i) p24 antigen production.
The
production of HIV-1 p24 antigen in cell culture supernatants was
determined by an ELISA (Abbott, Chicago, Ill.) according to the
manufacturer's protocol. All determinations were performed in
duplicate.
(ii) RT-PCR.
A semiquantitative reverse transcription-PCR
(RT-PCR) was used to evaluate the transcription of both unspliced and
multiply spliced viral RNAs in OM10 cells. Briefly, total RNA was
extracted from 2 × 106 cells with the RNAzolB
procedure (Tel-Test, Inc., Friendswood, Tex.), resuspended in
diethylpyrocarbonate-treated water, and quantified with a
spectrophotometer. The same amount of RNA (1 µg) was reverse
transcribed for 1 h at 37°C, with Moloney murine leukemia virus
reverse transcriptase (Gibco BRL, Grand Island, N.Y.) and random
hexanucleotides. Serial dilutions of cDNA were then amplified by PCR,
in the presence of 32P-radiolabeled dCTP and primers
specific for either HIV-1 unspliced RNAs (SK38 and SK39)
(17) or multispliced RNAs (MS1 and MS2) (38).
After 30 cycles of amplification, aliquots of amplified products were
separated in a 6% polyacrylamide gel and subsequently exposed to
autoradiography.
(iii) Intracytoplasmic detection of HIV-1 antigen.
Flow
cytometry was used to detect the expression of HIV-1 p24 antigen in
the cytoplasm of treated cells or controls. Cells were washed in
phosphate-buffered saline (PBS) and fixed and permeabilized in 250 µl
of PermeaFix (Gibco BRL) for 40 min. Cells were washed and labeled for
30 min at 4°C in 100 µl of PBS containing 0.2 µl of monoclonal
antibody (MAb) against HIV-1 p24 antigen (clone 314219 [American
Type Culture Collection]) or its appropriate control. After a second
wash, a fluorescein isothiocyanate (FITC)-conjugated secondary
anti-mouse antibody (Dako, Carpinteria, Calif.) was added for 30 min,
at 4°C. After the last wash, cells were resuspended in 0.5%
paraformaldehyde in PBS and analyzed on a Coulter Elite flow cytometer
(Coulter, Miami, Fla.), in parallel with the DNA content of the nuclei.
Flow cytometry analysis of cell phenotype. (i) Cell cycle.
The quantitative measure of cell cycle was performed by flow cytometry
analysis of nuclear DNA contents, after propidium iodide staining.
Briefly, cells were washed in PBS and fixed in 50% ethanol. After
washing, the nuclear DNA was treated with propidium iodide (50 µg/ml)
and RNase (10 mg/ml) for 20 min at room temperature. Cell cycle
determination was performed with a Coulter Elite flow cytometer and
analyzed with the help of Multicycleav software (Phoenix Flow, San
Diego, Calif.). At least 104 cells were assayed for each
determination.
(ii) Detection of apoptosis.
Annexin V is a
Ca2+-dependent, phospholipid-binding protein with high
affinity for phosphotidylserine. Normally, phosphotidylserine is found
only on the inner side of cell membranes, but during early phases of
apoptosis, cells lose membrane phospholipid asymmetry and expose
phosphotidylserine to the outer membrane. This process can be monitored
by using annexin V-FITC. 7-AAD is a nucleic acid stain that labels dead
cells with a compromised membrane. Used together, these two markers
allow for the discrimination among vital cells (7-AAD negative-annexin
negative), live cells early in apoptosis (7-AAD negative-annexin
positive), dead cells late in apoptosis (7-AAD positive-annexin
positive), and necrotic cells (7-AAD positive-annexin negative). Cell
samples (5 × 105) were washed with PBS and
resuspended in 0.5 ml of 1× binding buffer (BB) containing 10 µl of
FITC-conjugated annexin V (apoptosis detection kit; R&D Systems,
Minneapolis, Minn.) and 7-AAD (20 µg/ml) (Molecular Probes, Eugene,
Oreg.). Cells were incubated for 10 min at room temperature, washed
once with 1× BB, and fixed in 0.5 ml of 1× BB-1% alcohol-free
paraformaldehyde. These cells were analyzed on a Coulter Elite flow
cytometer. Apoptosis was also evaluated by the proportion of cells
harboring less than 1 N DNA in the nucleus, after staining with
propidium iodide.
(iii) Surface expression of differentiation markers.
Cell
surface expression of CD11b and CD14 was evaluated by cytofluorometric
analysis, with MAbs directly tagged with R-phycoerythrin and
FITC, respectively. Cells were washed in PBS, incubated at 4°C for 30 min with 5 µg of the specific MAbs per ml or the appropriate controls (Dako), washed again, and fixed in 1% paraformaldehyde prior
to their analysis on a Coulter Elite flow cytometer.
Phosphoprotein analysis. (i) Immunoblotting.
Protein (30 µg) obtained from a total cell lysate was resolved on 10%
polyacrylamide gels and electrotransferred to a nylon membrane (Protan
0.1 µm pore size; Schleicher and Schuell). The membrane was blocked
for 1 h at 22°C, probed overnight at 4°C with 0.5 µg of
4G-10 murine antiphosphotyrosine MAb (Upstate Biotechnology Inc., Lake
Placid, N.Y.) per ml, washed, and visualized with an ECL
chemiluminescence system (Amersham, Arlington Heights, Ill.).
(ii) Immunofluorescence.
The total tyrosine-phosphorylated
protein content was also evaluated by flow cytometry as described
previously with slight modifications (13). Briefly,
106 cells were washed in PBS, fixed and permeabilized with
PermeaFix (Ortho Diagnostics), washed again, and labeled for 30 min at
4°C with 1 µg of FITC-conjugated antiphosphotyrosine antibody
(Sigma) or its appropriate control. After a second wash, cells were
resuspended in 0.5% paraformaldehyde in PBS and analyzed by flow
cytometry.
 |
RESULTS |
Effect of genistein on HIV-1 expression in OM10 and U1
cells.
In initial experiments, OM10 cells exposed to
genistein for 4 h demonstrated an increase in HIV-1
replication as demonstrated by an increase in p24 antigen production at
day 3 postexposure. The increase in HIV-1 expression was found to
follow a dose response, with increasing doses of genistein from
25 to 100 µM resulting in an increase in HIV-1 p24 antigen
detected in culture supernatant (Fig.
1A). To determine if this observation was
restricted to the OM10 cell line, we examined the impact of
genistein on HIV-1 replication on a more differentiated
promonocytic cell line, U1. As previously observed with OM10 cells,
genistein enhanced HIV-1 production in U1 cells (Fig. 1B).
In contrast, the inactive analog of genistein, dazidzein, did
not increase HIV-1 p24 antigen production, indicating that the
observed effect is related to a specific biochemical activity of
genistein.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Genistein increases HIV-1 expression in OM10
and U1 cells. (A and B) OM10 cells (A) and U1 cells (B) were treated
with increasing doses of genistein for 4 h at 37°C,
washed in PBS, and resuspended (5 × 105 cells/ml) in
RPMI plus 10% fetal calf serum. Supernatants were collected at day 3. HIV-1 p24 antigen production was determined in duplicate by an
ELISA. Data are the means ± standard errors of the means of at
least five separate experiments. (Dazi represents cells treated with
dazidzein [100 µM]). (C) OM10 cells were cultured in the presence
of zidovudine (10 µg/ml) after the treatment with genistein.
Data are the means ± standard errors of the means of four
experiments expressed as ratios of p24 antigen production in
genistein-treated cells to that in controls.
|
|
Because OM10 cells remain CD4 positive despite being chronically
infected with HIV-1 (
5), we next determined if the
genistein-induced
increase in HIV-1 replication was due
predominantly to the induction
of proviral DNA already integrated
in the cell line or to reinfection
of cells. OM10 cells were treated
with zidovudine in addition
to genistein, and culture
supernatants were tested for the quantity
of HIV-1 p24 antigen
produced. The continued finding of increased
production of p24 antigen
in the zidovudine-treated cultures (Fig.
1C) indicates that
genistein effectively increases the ability
of the already
infected cell to support replication of its own
integrated provirus and
that reinfection of cells is unlikely
to play an important role in
the enhanced HIV-1 replication.
A semiquantitative RT-PCR analysis of HIV-1 RNA showed increased
levels of the multiply spliced RNA, as well as of unspliced
species in genistein-treated cells (Fig.
2), suggesting that the
increase of
HIV-1 replication in genistein-induced OM10 cells
is
predominantly transcriptional, which is consistent with the
transcriptional control in HIV-1 expression in this cell line
(
6).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Autoradiograph of semiquantitative RT-PCR analysis of
multiply spliced and unspliced HIV-1 RNAs in OM10 cells treated
with DMSO (control) or 100 µM genistein (gen) (induced).
Lanes a, b, c, d, and e represent 10-fold serial dilutions of 1 µg of
total RNA submitted to RT-PCR (as described in Materials and
Methods).
|
|
Effect of genistein on growth of OM10 cells.
Several
studies have demonstrated that genistein, in addition to
inhibiting tyrosine kinase, also may reduce cell proliferation, modify
the cell cycle, and induce cell differentiation (11, 19, 25, 41,
45). Because each of these cellular modifications may impact on
HIV-1 expression in chronically infected cells, the effects of
genistein on OM10 cells were examined. For cell growth
experiments, OM10 cells were treated for 4 h with
genistein at increasing concentrations, and the proportion of
viable cells was determined at days 1, 3, and 5. A dose-dependent
inhibition of cell growth was observed for genistein
concentrations between 12.5 and 100 µM, with a 50% inhibitory
concentration at 38 µM at day 3. At 50 µM, most cell proliferation
was inhibited; however, more than 80% of cells were still alive. Cell
toxicity appeared at 100 µM, with 35% of the cells being dead by 3 days (data not shown).
Effect of genistein on cell cycle progression.
To
evaluate the effect of genistein on the cell cycle, the DNA
content of OM10 cells was analyzed by flow cytometry at 24 h after
exposure to genistein. As shown in Fig.
3, genistein induced a strong
G2/M arrest of the cells at the concentrations shown to
induce HIV-1. The increase in the proportion of cells in
G2/M was first observed at a genistein
concentration of 25 µM but was more pronounced at 50 and 100 µM.
Time course analysis of the DNA content shows that this arrest appears
at 8 h, peaks between 16 and 24 h, and persists for at least
48 h postexposure (data not shown). The mitotic index (mean ± standard deviation, evaluated by counting the proportion of cells in
mitosis) was (2.3 ± 0.9)% (n = 3; counted on
103 cells) in genistein (100 µM)-treated cells
compared to (1.8 ± 0.5)% (n = 3; counted on
103 cells) in the control cells, indicating that cells are
arrested in G2 phase rather than in M.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Genistein induces a G2/M arrest in
OM10 cells. At day 1 after a 4-h induction with different
concentrations of genistein, the DNA content of nuclei of OM10
cells was determined by flow cytometry. The percentages of cells in
G1, S, and G2/M are shown as means of five
experiments (± standard errors of the means).
|
|
A significant increase in cells with less than 1N DNA present within
the nucleus was detected in the cells treated with the
highest
concentrations of genistein (Fig.
4A), suggesting that
genistein is
able to induce apoptosis in OM10 cells. This induction
of apoptosis was
confirmed by flow cytometry analysis of cells
stained with annexin V
and 7-AAD (Fig.
4B). In the cells treated
with 100 µM
genistein, 26% were positive for both annexin V and
7-AAD.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 4.
Genistein induces apoptosis in OM10 cells. (A)
After OM10 cells were washed and fixed in 50% ethanol, the nuclear DNA
was treated with propidium iodide and RNase for 20 min at room
temperature. Cell cycle determination was performed by flow cytometry.
The figure shows the percentages of cells with a DNA content in the
nucleus of less than 1N, 24 h after treatment of OM10 cells with
increasing concentrations of genistein. The numbers indicated
are means of five experiments (± standard errors of the means). (Dazi
represents cells treated with dazidzein [100 µM]). (B) A total of
10 × 105 cells were washed in PBS and, after
resuspension in BB containing 10 µl of FITC-conjugated annexin V and
7-AAD (20 µg/ml), were incubated, washed, and analyzed by flow
cytometry. The figure shows the dual staining of control and treated
cells with 7-AAD and annexin V. The percentages of cells present in
each quadrant are shown in the upper right corner. These data are from
one experiment representative of two separate experiments. gen,
genistein. The x and y axes denote log
fluorescence of FITC and 7-AAD, respectively.
|
|
Effect of genistein on cell differentiation.
In order
to determine the differentiation state of genistein-treated
cells, OM10 cells were evaluated at 5 days post-genistein exposure by morphologic analysis, by quantitation of surface
expression of CD14 and CD11b, and for induction of an NSE
activity. Genistein was found to induce profound changes in the
morphology of OM10 cells indicative of cell differentiation, including
enlargement of cells, induction of polymorphic and irregular shape,
indentation of the nuclei, less-apparent nucleoli, and increased
coarseness of chromatin (data not shown). Additionally, at the highest
concentrations (50 and 100 µM), NSE activity was induced within the
cells (Table 1), confirming the
differentiation effect of genistein. Flow cytometry analysis of
surface expression of CD14 and CD11b also indicated a significant
increase after genistein induction, at the highest
concentration tested (Table 1).
Dissociation between cell differentiation induced by
genistein and HIV-1 replication.
In cells of the
monocyte/macrophage lineage, a differentiation process is usually
associated with an increased susceptibility to HIV-1 infection
(22, 36, 40) or an increase in viral transcription of a
quiescent provirus (7, 26). However, differentiation has not
always been shown to enhance HIV-1 replication (14). We
found a similar dissociation in the OM10 cells. With dihydroxyvitamin D3, which is a strong inducer of OM10 cell differentiation,
there was no increase in HIV-1 replication (Table 1). Other
indirect evidence for this dissociation is the ability of
genistein to increase HIV-1 replication in the more
differentiated promonocytic cell line, U1 (Fig. 1C), and the finding
that the concentrations of genistein able to induce the
differentiation phenotype (>50 µM) are greater than those required
to significantly induce HIV-1 (25 µM).
Genistein-induced G2 arrest is associated
with enhanced HIV-1 replication.
Two approaches were used to
further investigate the precise role of the
genistein-induced cell cycle arrest in enhancing HIV-1 replication in OM10 cells. First, HIV-1 replication was examined following treatment with methylxanthine pentoxyfylline, which is known
to reverse G2 arrest induced by several DNA-damaging agents. In three separate experiments, pentoxyfylline was able to
alleviate the genistein-induced G2 arrest as
well as the genistein-induced enhanced HIV-1 replication
(Fig. 5). Thus, the increased production of HIV-1 appears to be related to the cell cycle arrest in
G2. In contrast, the proportion of cells with less than 1N
DNA was not reduced by methylxanthine pentoxyfylline, indicating that the induction of apoptosis by genistein was not directly
responsible for the increase in HIV-1 replication. Similarly, the
genistein-induced increase of surface expression of CD14 and
CD11b persisted in the presence of pentoxyfylline (data not shown),
confirming that the induction of HIV-1 was not linked to the
differentiation process. Since pentoxyfylline is also known as an
inhibitor of TNF-
synthesis (12), we measured the amount
of TNF-
in the supernatants of genistein-treated and control
cultures. At days 1 and 3 post-genistein exposure, TNF-
levels remained very low (below 15 pg) and did not differ between
genistein-treated cells and controls.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
Treatment with pentoxyfylline alleviates the
G2 arrest as well as the increase of HIV induced by
genistein. OM10 cells were treated with genistein or
DMSO alone, washed, and resuspended in RPMI with (right side) or
without (left side) pentoxyfylline (pentox) (1 mM). For DNA content
analysis by flow cytometry, cells were stained after 24 h with
propidium iodide as described in Materials and Methods. Below the
concentrations of genistein are the respective proportions of
cells arrested in G2 and with less than 1N DNA (data are
the means of four experiments). At day 3, supernatants were collected
for HIV-1 p24 antigen production. Values are expressed as ratios of
genistein-induced cells to controls (means of four
experiments ± standard errors of the means).
|
|
We next examined by flow cytometry, at 2 days postexposure, the effect
of genistein on intracytoplasmic HIV-1 p24 antigen
expression within cells located in G
1 compared to those
blocked
in G
2 (Table
2). In
the control cells, the mean proportion of
p24 antigen-expressing cells
did not significantly differ within
the G
1 and
G
2 phases (23 and 28%, respectively). In contrast,
within
the cells treated with 100 µM genistein, the mean proportion
of HIV-1-positive cells was significantly higher in
G
2 than in
G
1 (35 and 25%, respectively;
P < 0.02). This result confirms
that the
G
2 arrest mediated by genistein promotes a higher
HIV-1
expression in chronically infected cells.
The effects of genistein are related to the inhibition of
topoisomerase II activity and phosphatidylinositol turnover
rather than to tyrosine kinase inhibition.
To investigate
whether the induction of HIV-1 was due to the decrease of
tyrosine phosphorylation of a specific protein in the OM10 cells, we
analyzed the phosphotyrosine protein contents of treated cells. The
phosphotyrosine proteins were first analyzed in untreated and
genistein-induced cells, with immunoblotting with
antiphosphotyrosine. The basal level of phosphotyrosine was high
in OM10 cells, but surprisingly, no clear difference was observed
in genistein-treated cells in comparison to controls (data not
shown). This result suggests that the increase of HIV-1 may not be
a direct consequence of tyrosine kinase inhibition. Analysis by
flow cytometry of the total phosphotyrosine protein content of the
cells treated with genistein at concentrations up to 100 µM
demonstrated little reduction from controls (data not shown).
Additionally, another tyrosine kinase inhibitor, herbimycin A,
evaluated in a range of concentrations known to have significant tyrosine kinase inhibition (0.1 to 10 µM), failed to induce any increase of HIV-1 expression in the same OM10 cells (data not shown).
In addition to inhibiting tyrosine kinase, genistein has also
been shown to inhibit topoisomerase II activity
(
29) and phosphatidylinositol
turnover (
20). To
investigate whether either of these properties
of genistein was
involved in the induction of HIV-1 replication,
cells were treated
with (i) another inhibitor of topoisomerase
II activity,
etoposide; or (ii) a strong inhibitor of phosphatidylinositol
turnover,
psi-tectorigenin. In two independent experiments, OM10
cells treated
for 4 h with 1 to 4 µM etoposide produced a moderate
(2.1- to
2.8-fold) but reproducible increase of p24 antigen production,
as well
as a clear arrest of the cells in G
2/M (34 to 51% of cells
arrested at 24 h). Similarly, a strong and dose-dependent increase
of HIV-1 expression in OM10 cells treated with psi-tectorigenin
at
10 to 20 µg/ml was observed, in conjunction with a concomitant
arrest
at G
2/M. Of interest, pentoxyfylline was also able to
inhibit
both the enhanced HIV-1 replication and the G
2
arrest induced
by psi-tectorigenin (Fig.
6).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 6.
Induction of HIV-1 by psi-tectorigenin is also
linked to a G2/M arrest. OM10 cells were treated for 4 h with increasing concentrations of psi-tectorigenin or DMSO alone,
washed, and resuspended in RPMI with (right side) or without (left
side) pentoxyfylline (pentox) (1 mM). At day 3, supernatants were
collected for HIV-1 p24 antigen production. Values are expressed as
ratios of genistein-induced cells to controls (means of three
experiments ± standard errors of the means). Below each
concentration of psi-tectorigenin is the respective proportion of cells
arrested in G2/M (flow cytometric analysis of nuclear DNA
performed at day 1).
|
|
 |
DISCUSSION |
In this research paper, we describe the ability of the isoflavone
genistein to enhance the expression of HIV-1 in two
chronically infected monocytic cell lines, OM10 and U1. The
dose-dependent increase of HIV-1 p24 antigen production in the
supernatant of treated OM10 cells persisted in the presence of
zidovudine and was associated with an increase of both multiply spliced
and unspliced RNAs. These findings suggest an increase in transcription
of the integrated HIV-1 proviral DNA in genistein-treated
chronically infected cells. Our data suggest that this effect appears
to be independent of the inhibitory activity of genistein on
tyrosine kinase because there was no qualitative or quantitative
difference between the proteins phosphorylated on tyrosine residues of
treated cells and those on untreated cells, and another tyrosine
kinase inhibitor, herbimycin A, failed to increase HIV-1
replication. An alternative explanation is that an undetected
inhibition of the tyrosine phosphorylation of a minor protein could
cause these findings. However, two other properties of
genistein, its inhibition of phosphatidylinositol turnover and
its inhibition of topoisomerase II activity, seem to be
involved with induction of HIV-1 replication. Supporting findings
for these properties of genistein inducing HIV-1
replication include data demonstrating that psi-tectorigenin (an
inhibitor of phosphatidylinositol turnover) and etoposide (an inhibitor
of topoisomerase II activity) also upregulate HIV-1 replication.
Although we have not identified the molecular pathways that regulate
the transcriptional activation of HIV-1 by genistein, we have established a link between enhanced HIV-1 replication and
specific changes in cell phenotype. Of interest, we failed to identify
a specific association between cell differentiation and HIV-1
replication in the monocytic cell lines studied. These findings are
consistent with recent observations in U1 cells that also found a lack
of association between cell differentiation and HIV-1 replication
(15) and may be explained by the opposite effect of cell
differentiation on viral transcription and viral release described in
differentiated THP1 cells and monocyte-derived macrophages
(39).
Our findings support an association between the G2 arrest
induced by genistein in OM10 cells and enhanced HIV-1
replication. The ability of pentoxyfylline to prevent G2
arrest in genistein-treated cells with a concomitant reduction
in HIV-1 p24 antigen production to baseline supports the importance
of arresting the cells in G2 for upregulating HIV-1
replication. Additionally, we observed by flow cytometry a significant
increase of HIV-1 expression in cells arrested in G2
compared to cells located in S or G1. The in vivo
significance of this result is unclear. However, it is reasonable to
hypothesize that a virally induced modification of the cell cycle would
be important for HIV-1 to maximally produce viral progeny prior to
killing the infected cell. In support of this hypothesis, HIV-1 Vpr
has recently been shown to induce G2 arrest (2, 16,
21, 35, 37) by maintaining the cyclin-dependent kinase Cdc2 in an
inactive, phosphorylated form (16, 34, 35). Vpr is highly
conserved among different HIV-1 isolates and is also present in
HIV-2 and simian immunodeficiency virus (18). The
ability of Vpr to induce a G2 arrest is also observed among other species of lentiviruses (32), indicating that this
property may be an important strategy of the virus for continued
survival.
In further studies, recombinant purified Vpr protein has been shown to
increase HIV-1 replication after infection of promonocytic cell
lines or peripheral blood mononuclear cells and to reactivate virus in
latently infected cells (24). Additionally, an increase in
HIV-1 LTR activity has been associated with some domains of the Vpr
protein (10, 28, 44). Our findings correlating a G2 arrest with an increase in HIV-1 transcription
suggest that the cell cycle modifications associated with Vpr increase
viral transcription and that, by arresting the cell in G2,
provide a cellular environment conducive to enhanced HIV-1
replication (1, 44). The recent report (8) of an
increase of HIV-1 LTR activity and virus expression during the
G2 arrest caused by Vpr strengthens this hypothesis.
Moreover, the in vivo selection for the wild-type Vpr gene during human
or chimpanzee infection over a defective Vpr clone provides further
supporting evidence (8).
In total, our findings suggest that modification of the cell cycle may
represent an important strategy for HIV-1 to promote its own
replication that may be critical for the virus to maximally propagate
itself while infecting cells that are further programmed by the virus
for cell death (27). Increasing evidence suggests that
apoptosis follows the arrest of the cell in G2 induced
either by Vpr (43) or by cellular interactions between the
HIV-1 Env glycoprotein and CD4-expressing cells (23).
Further understanding of the interactions between HIV-1 and
alterations of the cell cycle will provide new insights into HIV-1
pathogenesis and could provide novel strategies for inhibiting
HIV-1 replication through manipulation of the cell cycle of
HIV-1-infected cells.
 |
ACKNOWLEDGMENTS |
This research was supported by grants AI39004 and AI27563, the
UCSD Center for AIDS Research (AI36214), and a fellowship from NATO for
J. Gozlan.
We acknowledge Karen Hsia for providing reagents and procedures used
for RT-PCR analysis, J. Nordberg and M. Lutz (Veterans Affairs
Hospital, Medical Center Laboratory, San Diego, Calif.) for flow
cytometry analysis, and J. Corbeil (Department of Medicine, University
of California, San Diego) for providing the MAb 314219.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Clinical
Sciences Building, University of California, San Diego, 9500 Gilman
Dr., La Jolla, CA 92093-0672. Phone: (619) 534-7170. Fax: (619)
534-7411. E-mail: saspector{at}ucsd.edu.
Present address: Laboratoire de Virologie, Hôpital
Saint-Antoine, 75012 Paris, France.
 |
REFERENCES |
| 1.
|
Agostini, I.,
J. M. Navarro,
F. Rey,
M. Bouhamdan,
R. Spire, and J. Sire.
1996.
The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB.
J. Mol. Biol.
261:599-606[Medline].
|
| 2.
|
Bartz, S.,
M. E. Rogel, and M. Emerman.
1996.
Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 checkpoint control.
J. Virol.
70:2324-2331[Abstract].
|
| 3.
|
Beaty, C. D.,
T. L. Franklin,
Y. Uehara, and C. B. Wilson.
1994.
Lipopolysaccharide-induced cytokine production in human monocyte: role of tyrosine phosphorylation in transmembrane signal transduction.
Eur. J. Immunol.
24:1278-1284[Medline].
|
| 4.
|
Briand, G.,
B. Barbeau, and M. Tremblay.
1997.
Binding of HIV-1 to its receptor induces tyrosine phosphorylation of several CD4-associated proteins, including the phosphatidylinositol 3-kinase.
Virology
228:171-179[Medline].
|
| 5.
|
Butera, S. T.,
V. L. Perez,
B.-Y. Wu,
G. J. Nabel, and T. M. Folks.
1991.
Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection.
J. Virol.
65:4645-4653[Abstract/Free Full Text].
|
| 6.
|
Butera, S. T.,
B. D. Roberts,
L. Lam,
T. Hodge, and T. M. Folks.
1994.
Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency.
J. Virol.
68:2726-2730[Abstract/Free Full Text].
|
| 7.
|
Cannon, P. M.,
D. G. Tenen,
M. B. Feinberg,
H. S. Shin, and S. Kim.
1993.
Human immunodeficiency virus-1 infection of the human promyelocytic cell line HL-60: high frequency of low level infection and effect of subsequent cell differentiation.
Blood
81:437-445[Abstract/Free Full Text].
|
| 8.
|
Chun Goh, W.,
M. E. Rogel,
M. Kinsey,
S. F. Michael,
P. N. Fultz,
M. A. Nowak,
B. H. Hanh, and M. Emerman.
1998.
HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.
Nat. Med.
4:65-71[Medline].
|
| 9.
|
Cohen, D. I.,
Y. Tani,
H. Tian,
E. Boone,
L. E. Samelson, and H. C. Lane.
1992.
Participation of tyrosine phosphorylation in the cytopathic effect of human immunodeficiency virus-1.
Science
256:542-545[Abstract/Free Full Text].
|
| 10.
|
Cohen, E. A.,
E. F. Terwilliger,
Y. Jalinosa,
J. Proulx,
J. G. Sodroski, and W. A. Haseline.
1990.
Identification of HIV-1 vpr products and function.
J. Acquired Immune Defic. Syndr.
3:11-18.
|
| 11.
|
Constantinou, A.,
K. Kiguchi, and E. Huberman.
1990.
Induction of differentiation and DNA strand breakage in human HL-60 and K562 leukemia cells by genistein.
Cancer Res.
50:2618-2624[Abstract/Free Full Text].
|
| 12.
|
Dezube, B. J.
1994.
Pentoxifylline for the treatment of infection with human immunodeficiency virus.
Clin. Infect. Dis.
18:285-287[Medline].
|
| 13.
|
Far, D. F.,
J.-F. Peyron,
V. Imbert, and B. Rossi.
1994.
Immunofluorescent quantification of tyrosine phosphorylation of cellular proteins in whole cells by flow cytometry.
Cytometry
15:327-334[Medline].
|
| 14.
|
Gaynor, R.
1992.
Cellular transcription factors involved in the regulation of HIV-1 gene expression.
AIDS
6:347-363[Medline].
|
| 15.
|
Goletti, D.,
A. L. Kinter,
P. Biswas,
S. M. Bende,
G. Poli, and A. S. Fauci.
1995.
Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression.
J. Virol.
69:2540-2546[Abstract].
|
| 16.
|
He, J.,
S. Choe,
R. Walker,
P. DiMarzio,
D. O. Morgan, and N. R. Landau.
1995.
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
J. Virol.
69:6705-6711[Abstract].
|
| 17.
|
Hsia, K.,
D. H. Spector, and S. A. Spector.
1997.
Molecular analysis of the differential restriction of human immunodeficiency virus type 1 replication in neuronal cell lines.
J. Gen. Virol.
78:3255-3264[Abstract].
|
| 18.
|
Huang, L. M., and K. T. Jeang.
1995.
HIV vpr: roles in viral replication and cellular metabolism, p. 3-9.
In
G. Meyers, et al. (ed.), Human retrovirus and AIDS. Theoretical Biology and Biophysics, Los Alamos, N.Mex.
|
| 19.
|
Hunàkovà, L.,
J. Sedlàk,
M. Klobusickà,
J. Durai, and B. Chorvàth.
1994.
Tyrosine kinase inhibitor-induced differentiation of K-562 cells: alterations of cell cycle cycle and cell surface phenotype.
Cancer Lett.
81:81-87[Medline].
|
| 20.
|
Imoto, M.,
T. Yamashita,
T. Sawa,
S. Kurasawa,
H. Naganawa,
T. Takeuchi,
Z. Bao-quan, and K. Umeawa.
1988.
Inhibition of cellular phosphatidylinositol furnover by psi-tectorigenin.
FEBS Lett.
230:230-243.
|
| 21.
|
Jowett, J. B.,
V. Planelles,
B. Poon,
N. P. Shah,
M. L. Chen, and S. Y. Chen.
1995.
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.
J. Virol.
69:6304-6313[Abstract].
|
| 22.
|
Kitano, K.,
G. C. Baldwin,
M. A. Raines, and D. W. Golde.
1990.
Differentiating agents facilitate infection of myeloid leukemia cell lines by monocytotrophic HIV-1 strains.
Blood
76:1980-1988[Abstract/Free Full Text].
|
| 23.
|
Kolesnitchenko, V.,
L. M. Wahl,
H. Tian,
I. Sunila,
T. Yoshihiko,
D.-P. Hartmann,
J. Cossman,
M. Raffeld,
J. Orenstein,
E. Samelson, and D. J. Cohen.
1995.
Human immunodeficiency virus 1 envelope-initiated G2-phase programmed cell death.
Proc. Natl. Acad. Sci. USA
142:1880-1893.
|
| 24.
|
Levy, D. N.,
Y. Refaeli, and D. B. Weiner.
1995.
Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency.
J. Virol.
69:1243-1252[Abstract].
|
| 25.
|
Makishima, M.,
Y. Honma,
M. Hozumi,
K. Sampi,
M. Hattori,
K. Umezawa, and K. Moyoyoshi.
1991.
Effects of inhibitors of protein tyrosine kinase activity and/or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells.
Leuk. Res.
15:701-708[Medline].
|
| 26.
|
Moses, A. V.,
C. Ibanez,
R. Gaynor,
P. Ghazal, and J. A. Nelson.
1994.
Differential role of long terminal repeat control elements for the regulation of basal and Tat-mediated transcription of the human immunodeficiency virus in stimulated and unstimulated primary human macrophages.
J. Virol.
68:298-307[Abstract/Free Full Text].
|
| 27.
|
Noraz, N.,
J. Gozlan,
J. Corbeil,
T. Brunner, and S. A. Spector.
1997.
HIV-induced apoptosis of activated primary CD4+ T lymphocytes is not mediated by Fas/Fas ligand.
AIDS
11:1671-1680[Medline].
|
| 28.
|
Ogawa, K.,
R. Shibata,
T. Kiyomasu,
I. Higuchi,
Y. Kishida,
A. Ishimoto, and A. Adachi.
1989.
Mutational analysis of the human immunodeficiency virus vpr open reading frame.
J. Virol.
63:4110-4114[Abstract/Free Full Text].
|
| 29.
|
Okura, A.,
H. Arakawa,
H. Oka,
T. Yoshinari, and Y. Monden.
1988.
Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells.
Biochem. Biophys. Res. Commun.
157:183-189[Medline].
|
| 30.
|
Orenstein, J. M.,
C. Fox, and S. M. Wahl.
1997.
Macrophages as a source of HIV during opportunistic infections.
Science
276:1857-1861[Abstract/Free Full Text].
|
| 31.
|
Phipps, D. J.,
S. E. Read,
J. P. Piovesan,
G. B. Mills, and D. R. Branch.
1996.
HIV infection in vitro enhances the activity of src-family protein tyrosine kinase.
AIDS
10:1191-1198[Medline].
|
| 32.
|
Planelles, V.,
J. B. Jowett,
O. Li,
Y. Xie,
B. Hahn, and S. Y. Chen.
1996.
Vpr-induced cell cycle arrest is conserved among primate lentiviruses.
J. Virol.
70:2516-2524[Abstract].
|
| 33.
|
Poli, G.,
P. Bressler,
A. Kinter,
E. Duh,
W. C. Timmer,
A. Rabson,
J. S. Justement,
S. Stanley, and A. S. Fauci.
1990.
Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor by transcriptional and post-transcriptional mechanisms.
J. Exp. Med.
172:151-158[Abstract/Free Full Text].
|
| 34.
|
Poon, B.,
B. M. Jowett,
S. A. Stewart,
R. W. Armstrong,
G. M. Rishton, and I. S. Y. Chen.
1997.
Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard.
J. Virol.
71:3961-3971[Abstract].
|
| 35.
|
Re, F.,
D. Braaten,
E. K. Franke, and J. Luban.
1995.
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.
J. Virol.
69:6859-6864[Abstract].
|
| 36.
|
Rich, E. A.,
I. S. Y. Chen,
J. A. Zack,
M. L. Leonard, and W. A. O'Brien.
1992.
Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV 1).
J. Clin. Investig.
89:176-183.
|
| 37.
|
Rogel, M.,
L. Wu, and M. Emerman.
1995.
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.
J. Virol.
69:882-888[Abstract].
|
| 38.
|
Saskela, K.,
E. Muchmore,
M. Girard,
P. Fultz, and D. Baltimore.
1993.
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees.
J. Virol.
67:7423-7427[Abstract/Free Full Text].
|
| 39.
|
Shattock, R. J.,
J. S. Friedland, and G. E. Griffin.
1993.
Release of human immunodeficiency virus by THP-1 and human macrophages is regulated by cellular adherence and activation.
J. Virol.
67:3569-3575[Abstract/Free Full Text].
|
| 40.
|
Sonza, S.,
A. Maerz,
N. Deacon,
J. Meanger,
J. Mills, and S. Crowe.
1996.
Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes.
J. Virol.
70:3863-3869[Abstract].
|
| 41.
|
Spinozzi, F.,
C. Pagliacci,
G. Migliorati,
R. Moraca,
F. Grignani,
C. Riccardi, and I. Nicoletti.
1994.
The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in jurkat T-leukemia cells.
Leuk. Res.
18:431-439[Medline].
|
| 42.
|
Stefanova, I.,
M. L. Corcoran,
E. M. Horak,
L. M. Wahk,
J. B. Bolen, and I. D. Horak.
1993.
Lipopolysaccharide induces activation of CD14-associated protein tyrosine kinase p53/56lyn.
J. Biol. Chem.
268:20725-20728[Abstract/Free Full Text].
|
| 43.
|
Stewart, S. A.,
B. Poon,
J. B. M. Jowett, and I. S. Y. Chen.
1997.
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest.
J. Virol.
71:5579-5592[Abstract].
|
| 44.
|
Wang, L.,
S. Mukherjee,
F. Jia,
O. Narayan, and L. J. Zhao.
1995.
Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activator of viral long terminal repeat.
J. Biol. Chem.
270:25564-25569[Abstract/Free Full Text].
|
| 45.
|
Watanabe, T.,
K. Kondo, and M. Oishi.
1991.
Induction of differentiation of mouse erythroleukemia cells by genistein, an inhibitor of tyrosine protein kinases.
Cancer Res.
51:764-768[Abstract/Free Full Text].
|
| 46.
|
Weinstein, S. L.,
C. H. June, and A. L. DeFranco.
1993.
Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14.
J. Immunol.
151:3829-3838[Abstract].
|
| 47.
|
Weinstein, S. L.,
J. S. Sanghera,
K. Lemke,
A. L. DeFranco, and S. L. Pelech.
1992.
Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages.
J. Biol. Chem.
267:14955-14962[Abstract/Free Full Text].
|
Journal of Virology, October 1998, p. 8174-8180, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Andres, A., Donovan, S. M., Kuhlenschmidt, T. B., Kuhlenschmidt, M. S.
(2007). Isoflavones at Concentrations Present in Soy Infant Formula Inhibit Rotavirus Infection in Vitro. J. Nutr.
137: 2068-2073
[Abstract]
[Full Text]
-
Knight, G. L., Turnell, A. S., Roberts, S.
(2006). Role for Wee1 in Inhibition of G2-to-M Transition through the Cooperation of Distinct Human Papillomavirus Type 1 E4 Proteins.. J. Virol.
80: 7416-7426
[Abstract]
[Full Text]
-
Schlaepfer, E., Audige, A., Joller, H., Speck, R. F.
(2006). TLR7/8 Triggering Exerts Opposing Effects in Acute versus Latent HIV Infection.. J. Immunol.
176: 2888-2895
[Abstract]
[Full Text]
-
Groschel, B., Bushman, F.
(2005). Cell Cycle Arrest in G2/M Promotes Early Steps of Infection by Human Immunodeficiency Virus. J. Virol.
79: 5695-5704
[Abstract]
[Full Text]
-
Thierry, S., Marechal, V., Rosenzwajg, M., Sabbah, M., Redeuilh, G., Nicolas, J.-C., Gozlan, J.
(2004). Cell Cycle Arrest in G2 Induces Human Immunodeficiency Virus Type 1 Transcriptional Activation through Histone Acetylation and Recruitment of CBP, NF-{kappa}B, and c-Jun to the Long Terminal Repeat Promoter. J. Virol.
78: 12198-12206
[Abstract]
[Full Text]
-
Chen, C.-J., Makino, S.
(2004). Murine Coronavirus Replication Induces Cell Cycle Arrest in G0/G1 Phase. J. Virol.
78: 5658-5669
[Abstract]
[Full Text]